Literature DB >> 21071708

Reduction in hexokinase II levels results in decreased cardiac function and altered remodeling after ischemia/reperfusion injury.

Rongxue Wu1, Kirsten M Smeele, Eugene Wyatt, Yoshihiko Ichikawa, Otto Eerbeek, Lin Sun, Kusum Chawla, Markus W Hollmann, Varun Nagpal, Sami Heikkinen, Markku Laakso, Kentaro Jujo, J Andrew Wasserstrom, Coert J Zuurbier, Hossein Ardehali.   

Abstract

RATIONALE: Cardiomyocytes switch substrate utilization from fatty acid to glucose under ischemic conditions; however, it is unknown how perturbations in glycolytic enzymes affect cardiac response to ischemia/reperfusion (I/R). Hexokinase (HK)II is a HK isoform that is expressed in the heart and can bind to the mitochondrial outer membrane.
OBJECTIVE: We sought to define how HKII and its binding to mitochondria play a role in cardiac response and remodeling after I/R. METHODS AND
RESULTS: We first showed that HKII levels and its binding to mitochondria are reduced 2 days after I/R. We then subjected the hearts of wild-type and heterozygote HKII knockout (HKII(+/)⁻) mice to I/R by coronary ligation. At baseline, HKII(+/)⁻ mice have normal cardiac function; however, they display lower systolic function after I/R compared to wild-type animals. The mechanism appears to be through an increase in cardiomyocyte death and fibrosis and a reduction in angiogenesis; the latter is through a decrease in hypoxia-inducible factor-dependent pathway signaling in cardiomyocytes. HKII mitochondrial binding is also critical for cardiomyocyte survival, because its displacement in tissue culture with a synthetic peptide increases cell death. Our results also suggest that HKII may be important for the remodeling of the viable cardiac tissue because its modulation in vitro alters cellular energy levels, O₂ consumption, and contractility.
CONCLUSIONS: These results suggest that reduction in HKII levels causes altered remodeling of the heart in I/R by increasing cell death and fibrosis and reducing angiogenesis and that mitochondrial binding is needed for protection of cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21071708      PMCID: PMC3017633          DOI: 10.1161/CIRCRESAHA.110.223115

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  34 in total

1.  Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis.

Authors:  John G Pastorino; Nataly Shulga; Jan B Hoek
Journal:  J Biol Chem       Date:  2001-12-18       Impact factor: 5.157

2.  A reevaluation of the roles of hexokinase I and II in the heart.

Authors:  Richard Southworth; Katherine A B Davey; Alice Warley; Pamela B Garlick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-09-01       Impact factor: 4.733

3.  Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart.

Authors:  E D Abel; H C Kaulbach; R Tian; J C Hopkins; J Duffy; T Doetschman; T Minnemann; M E Boers; E Hadro; C Oberste-Berghaus; W Quist; B B Lowell; J S Ingwall; B B Kahn
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

4.  Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function.

Authors:  A A Kocher; M D Schuster; M J Szabolcs; S Takuma; D Burkhoff; J Wang; S Homma; N M Edwards; S Itescu
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

5.  Elevated expression of hexokinase II protects human lung epithelial-like A549 cells against oxidative injury.

Authors:  Aftab Ahmad; Shama Ahmad; B Kelly Schneider; Corrie B Allen; Ling-Yi Chang; Carl W White
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-09       Impact factor: 5.464

6.  Regulation of hypoxia-inducible factor 1 by glucose availability under hypoxic conditions.

Authors:  Jing Zhou; Kenta Hara; Masahiro Inoue; Suirin Hamada; Hisafumi Yasuda; Hiroaki Moriyama; Hiroko Endo; Kiichi Hirota; Kazuyoshi Yonezawa; Masao Nagata; Koichi Yokono
Journal:  Kobe J Med Sci       Date:  2008-02-08

7.  Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II.

Authors:  Lin Sun; Shetha Shukair; Tejaswitha Jairaj Naik; Farzad Moazed; Hossein Ardehali
Journal:  Mol Cell Biol       Date:  2007-11-26       Impact factor: 4.272

8.  Ischemic preconditioning affects hexokinase activity and HKII in different subcellular compartments throughout cardiac ischemia-reperfusion.

Authors:  Ebru Gürel; Kirsten M Smeele; Otto Eerbeek; Anneke Koeman; Cihan Demirci; Markus W Hollmann; Coert J Zuurbier
Journal:  J Appl Physiol (1985)       Date:  2009-02-19

9.  Phosphorylation barriers to skeletal and cardiac muscle glucose uptakes in high-fat fed mice: studies in mice with a 50% reduction of hexokinase II.

Authors:  Patrick T Fueger; Robert S Lee-Young; Jane Shearer; Deanna P Bracy; Sami Heikkinen; Markku Laakso; Jeffrey N Rottman; David H Wasserman
Journal:  Diabetes       Date:  2007-07-16       Impact factor: 9.461

10.  The Hedgehog transcription factor Gli3 modulates angiogenesis.

Authors:  Marie-Ange Renault; Jérôme Roncalli; Jörn Tongers; Sol Misener; Tina Thorne; Kentaro Jujo; Aiko Ito; Trevor Clarke; Chris Fung; Meredith Millay; Christine Kamide; Andrew Scarpelli; Ekaterina Klyachko; Douglas W Losordo
Journal:  Circ Res       Date:  2009-09-03       Impact factor: 17.367

View more
  39 in total

1.  Hexokinase cellular trafficking in ischemia-reperfusion and ischemic preconditioning is altered in type I diabetic heart.

Authors:  Ebru Gurel; Savas Ustunova; Aysegul Kapucu; Nadim Yilmazer; Otto Eerbeek; Rianne Nederlof; Markus W Hollmann; Cihan Demirci-Tansel; Coert J Zuurbier
Journal:  Mol Biol Rep       Date:  2013-05-08       Impact factor: 2.316

Review 2.  Hexokinases and cardioprotection.

Authors:  Guillaume Calmettes; Bernard Ribalet; Scott John; Paavo Korge; Peipei Ping; James N Weiss
Journal:  J Mol Cell Cardiol       Date:  2014-09-26       Impact factor: 5.000

Review 3.  Bioanalysis of eukaryotic organelles.

Authors:  Chad P Satori; Michelle M Henderson; Elyse A Krautkramer; Vratislav Kostal; Mark D Distefano; Mark M Distefano; Edgar A Arriaga
Journal:  Chem Rev       Date:  2013-04-10       Impact factor: 60.622

Review 4.  Recent advances in mitochondrial research.

Authors:  Bradford G Hill
Journal:  Circ Res       Date:  2013-12-06       Impact factor: 17.367

5.  Acute inhibition of GSK causes mitochondrial remodeling.

Authors:  Tiffany Nguyen; Renee Wong; Guanghui Wang; Marjan Gucek; Charles Steenbergen; Elizabeth Murphy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-30       Impact factor: 4.733

6.  Assessing the early changes of cerebral glucose metabolism via dynamic (18)FDG-PET/CT during cardiac arrest.

Authors:  Ying-Qing Li; Xiao-Xing Liao; Jian-Hua Lu; Rong Liu; Chun-Lin Hu; Gang Dai; Xiang-Song Zhang; Xin-Chong Shi; Xin Li
Journal:  Metab Brain Dis       Date:  2015-02-24       Impact factor: 3.584

7.  Pathophysiological consequences of TAT-HKII peptide administration are independent of impaired vascular function and ensuing ischemia.

Authors:  Rianne Nederlof; Chaoqin Xie; Otto Eerbeek; Anneke Koeman; Dan M J Milstein; Markus W Hollmann; Egbert G Mik; Alice Warley; Richard Southworth; Fadi G Akar; Coert J Zuurbier
Journal:  Circ Res       Date:  2013-01-18       Impact factor: 17.367

Review 8.  Nutrient-sensing mTORC1: Integration of metabolic and autophagic signals.

Authors:  Valerie P Tan; Shigeki Miyamoto
Journal:  J Mol Cell Cardiol       Date:  2016-01-07       Impact factor: 5.000

9.  High-fat load: mechanism(s) of insulin resistance in skeletal muscle.

Authors:  D S Lark; K H Fisher-Wellman; P D Neufer
Journal:  Int J Obes Suppl       Date:  2012-12

Review 10.  Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia-reperfusion injury in heart.

Authors:  Rianne Nederlof; Otto Eerbeek; Markus W Hollmann; Richard Southworth; Coert J Zuurbier
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.